Rachele BUSCA
Director, HTA and Real-World Evidence EMEACLA - Edwards Lifesciences
Taking the ‘Risk’ out of ‘Risk Sharing Agreements’: Leveraging RWE to Connect Regulatory, Innovative Funding Models, and Product Adoption
Wednesday 31 May 12:00 - 12:50
Innovative Payment Schemes (IPSs) in Europe: springboard for innovation?
Wednesday 31 May 14:00 - 14:50
Market Access expert, Director level professional, with over 15 years of experience in Medical Device delivering data and tools to effect reimbursement, funding, and Health Technology Assessments. Currently Director of HTA and Real-World evidence, EMEACLA at Edwards Lifesciences. Previously served as EMEA Leader Health Economics at W.L GORE – a Global Devices manufacturer known for innovation and a modern, distinctive company culture. Worked for over 7 years in the Italian Pharmaceutical business and in consultancy group Pbe. Director Pricing and Reimbursement Strategy at BTG and Principal Manager at Medtronic assisting several divisions: pulmonology, cardiology, cardiac disease management, structural heart, peripheral.
